SCHEMBL24257715

SCHEMBL24257715

CCOC(=O)CNC(=O)c1ncc(-c2cn(-c3ccccc3)nn2)c(C)c1O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 6/20 0.53
HPGD P15428 1/20 0.43
RXFP1 Q9HBX9 1/20 0.42
ALDH1A1 P00352 1/20 0.42
APP P05067 1/20 0.41
RAB9A P51151 3/20 0.40
GAA P10253 1/20 0.40
NPC1 O15118 3/20 0.39
PPID Q08752 1/20 0.39
DGAT1 O75907 1/20 0.38
TRPC1 P48995 1/20 0.38
TRPC3 Q13507 1/20 0.38
STIM1 Q13586 1/20 0.38
ORAI1 Q96D31 1/20 0.38
STIM2 Q9P246 1/20 0.38
TP53 P04637 1/20 0.38
POLB P06746 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257796 0.91 EGLN1 (0.47) EGLN1HPGDALDH1A1RAB9AGAA
SCHEMBL24257555 0.89 EGLN1 (0.66) EGLN1
SCHEMBL24257699 0.84 HPGD (0.44) EGLN1HPGDRXFP1ALDH1A1RAB9A
SCHEMBL30453755 0.83 EGLN1 (0.49) EGLN1
SCHEMBL24257814 0.81 HPGD (0.46) EGLN1HPGDRXFP1ALDH1A1RAB9A
SCHEMBL24257559 0.81 EGLN1 (0.59) EGLN1
SCHEMBL24257683 0.80 LMNA (0.50) EGLN1HPGDALDH1A1RAB9AGAA
SCHEMBL30546867 0.80 LMNA (0.50) EGLN1HPGDALDH1A1RAB9AGAA
SCHEMBL30453015 0.80 LMNA (0.50) EGLN1HPGDALDH1A1RAB9AGAA
SCHEMBL24257722 0.80 HPGD (0.48) HPGDRXFP1ALDH1A1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 EGLN1 19/4885HPGD 109/4885RXFP1 470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.